Open an account

Psyence Biomedical

PBM · NASDAQ

$4.17+$0.045 (+1.09%)TodayMarket closed ·
Prev close $4.12

About PBM

Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

Employees
12
Headquarters
TORONTO, Ontario
Listed
Dec 10, 2021
Sector
Health Care
Industry
Biotechnology
Website
psyencebiomed.com

PBM key statistics

Market cap
15.89M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
51.54K
Volume
13.19K
Open price
$4.11
High today
$4.29
Low today
$4.06
52 Week high
$21.50
52 Week low
$1.92

Psyence Biomedical (PBM) at a glance

Psyence Biomedical (PBM) last traded at $4.17, with a market cap of 15.89M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.06 and $4.29. The current price is 2.6% above the day's low and 2.9% below its high.

Volume so far is 13.19K shares, below the average of 51.54K shares a day.

Over the past year Psyence Biomedical has ranged from $1.92 to $21.50, and now sits 11% of the way up that range.

PBM news

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Kaustubh Bagalkote

    Why Is Psyence Biomedical Stock Falling Wednesday?

  • Henry Khederian

    PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

  • Avi Kapoor

    Dow Jumps Over 600 Points; Netflix Shares Tumble After Q1 Results

  • 'Trump To Sign Executive Order On Psychedelic Drug Used Abroad To Treat PTSD' - CBS News Exclusive

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.